Literature DB >> 16493000

Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma.

Jennifer L Chan1, Katherine C Tang, Anoop P Patel, Larissa M Bonilla, Nicola Pierobon, Nicholas M Ponzio, Pranela Rameshwar.   

Abstract

Mesenchymal stem cells (MSCs) are mostly found around the vasculature system of the adult bone marrow (BM). They function as immune suppressors, express MHC-II, are phagocytic, and support T-cell cytotoxicity. We hypothesize that these contradictory properties of MSCs are important for BM homeostasis and occur partly through antigen presentation (antigen-presenting cells [APCs]) within a narrow window. Indeed, we have verified APC functions of MSCs to recall antigens, Candida albicans and Tetanus toxoid. The target cells have been identified to be CD4(+) T cells. APC assays with IFNgamma-knockdown MSCs and with anti-IFNgamma receptor confirmed that MHC-II expression requires autocrine stimulation by IFNgamma. During APC functions, as IFNgamma levels become elevated, there was a concomitant decrease in MHC-II on MSCs. This observation was correlated with flow cytometry studies showing a gradual decrease in MHC-II expression as IFNgamma levels were increased. The reduced levels of MHC-II correlated with losses in their allogeneic potential, as indicated in mixed lymphocyte reaction. In summary, endogenous and low levels of IFNgamma are required for MHC-II expression on MSCs, and for APC functions. APC functions occur during a narrow window before IFNgamma levels are increased. The study has implications for BM protection against infection and exacerbated inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493000      PMCID: PMC1895812          DOI: 10.1182/blood-2006-01-0057

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  Inflammation, a prototype for organogenesis of the lymphopoietic/hematopoietic system.

Authors:  S I Nishikawa; H Hashi; K Honda; S Fraser; H Yoshida
Journal:  Curr Opin Immunol       Date:  2000-06       Impact factor: 7.486

2.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model.

Authors:  D C Chow; L A Wenning; W M Miller; E T Papoutsakis
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

3.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models.

Authors:  D C Chow; L A Wenning; W M Miller; E T Papoutsakis
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

4.  Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells.

Authors:  Kathleen A Hinds; Jonathan M Hill; Erik M Shapiro; Mikko O Laukkanen; Alfonso C Silva; Christian A Combs; Timothy R Varney; Robert S Balaban; Alan P Koretsky; Cynthia E Dunbar
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

Review 5.  Prometheus's vulture and the stem-cell promise.

Authors:  Nadia Rosenthal
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

6.  Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell.

Authors:  John Stagg; Sandra Pommey; Nicoletta Eliopoulos; Jacques Galipeau
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

7.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

8.  Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.

Authors:  S M Devine; A M Bartholomew; N Mahmud; M Nelson; S Patil; W Hardy; C Sturgeon; T Hewett; T Chung; W Stock; D Sher; S Weissman; K Ferrer; J Mosca; R Deans; A Moseley; R Hoffman
Journal:  Exp Hematol       Date:  2001-02       Impact factor: 3.084

Review 9.  Bone marrow stromal stem cells: nature, biology, and potential applications.

Authors:  P Bianco; M Riminucci; S Gronthos; P G Robey
Journal:  Stem Cells       Date:  2001       Impact factor: 6.277

Review 10.  Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity.

Authors:  Edward F Rosloniec; Kary Latham; Yajaira B Guedez
Journal:  Arthritis Res       Date:  2002-07-17
View more
  150 in total

Review 1.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

2.  Emerging roles for multipotent, bone marrow-derived stromal cells in host defense.

Authors:  Jeffery J Auletta; Robert J Deans; Amelia M Bartholomew
Journal:  Blood       Date:  2012-01-06       Impact factor: 22.113

Review 3.  Moving from the laboratory bench to patients' bedside: considerations for effective therapy with stem cells.

Authors:  Lauren S Sherman; Jessian Munoz; Shyam A Patel; Meneka A Dave; Ilani Paige; Pranela Rameshwar
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

Review 4.  Multipotent mesenchymal stromal cells and the innate immune system.

Authors:  Katarina Le Blanc; Dimitrios Mougiakakos
Journal:  Nat Rev Immunol       Date:  2012-04-25       Impact factor: 53.106

Review 5.  Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells.

Authors:  Chao Shi
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 6.  Mesenchymal stem cells: Mechanisms of immunomodulation and homing.

Authors:  Hiroshi Yagi; Alejandro Soto-Gutierrez; Biju Parekkadan; Yuko Kitagawa; Ronald G Tompkins; Naoya Kobayashi; Martin L Yarmush
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

Review 7.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

8.  Donor variability among anti-inflammatory pre-activated mesenchymal stromal cells.

Authors:  Andrea Gray; Rene S Schloss; Martin Yarmush
Journal:  Technology (Singap World Sci)       Date:  2016-09

Review 9.  Would cancer stem cells affect the future investment in stem cell therapy.

Authors:  Pranela Rameshwar
Journal:  World J Exp Med       Date:  2012-04-20

Review 10.  Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions.

Authors:  Jeffery J Auletta; Kenneth R Cooke; Luis A Solchaga; Robert J Deans; Wouter van't Hof
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.